Viamet Presents Phase 2b Results Demonstrating Unprecedented Efficacy of Oral VT-1161 in the Treatment of Recurrent Vulvovaginal Candidiasis

Late-breaker poster at ASM Microbe 2017 represents the first scientific presentation of the Company’s REVIVE Study data

Viamet Pharmaceuticals, Inc. today announced the presentation of multiple studies supporting VT-1161, the Company’s lead product candidate for the treatment of fungal infections, at the American Society for Microbiology’s ASM Microbe 2017 in New Orleans, Louisiana. VT-1161 is a highly potent and selective, orally available inhibitor of fungal CYP51 that has demonstrated broad-spectrum activity against yeast, dermatophyte, endemic and multi-drug resistant fungal pathogens. The Phase 2b REVIVE study, presented during the late-breaker poster session, demonstrated unprecedented efficacy in women diagnosed with recurrent vulvovaginal candidiasis (RVVC). All VT-1161 treatment arms in the per protocol and intent-to-treat analyses achieved statistical significance versus placebo for the study primary endpoint. VT-1161 was well tolerated with a favorable safety profile.